Tech Company Financing Transactions

Monte Rosa Therapeutics Funding Round

Monte Rosa Therapeutics, based in Boston, received $96 million from Aisling Capital, Amzak Health Investors and Cambridge Asset Management.

Transaction Overview

Announced On
9/25/2020
Transaction Type
Venture Equity
Amount
$96,000,000
Round
Series B
Proceeds Purpose
This financing will enable Monte Rosa to accelerate the growth of its pipeline, advance development candidates into the clinic and bolster its platform capabilities to rationally design and develop small molecule degraders (also known as molecular glues) that hijack the body's innate ability to degrade proteins.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
40 Guest St.
Boston, MA 02135
USA
Phone
Undisclosed
Email Address
Overview
Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020.
Profile
Monte Rosa Therapeutics LinkedIn Company Profile
Social Media
Monte Rosa Therapeutics Company Twitter Account
Company News
Monte Rosa Therapeutics News
Facebook
Monte Rosa Therapeutics on Facebook
YouTube
Monte Rosa Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Markus Warmuth
  Markus Warmuth LinkedIn Profile  Markus Warmuth Twitter Account  Markus Warmuth News  Markus Warmuth on Facebook
Chief Financial Officer
Ajim Tamboli
  Ajim Tamboli LinkedIn Profile  Ajim Tamboli Twitter Account  Ajim Tamboli News  Ajim Tamboli on Facebook
Chief Scientific Officer
John Castle
  John Castle LinkedIn Profile  John Castle Twitter Account  John Castle News  John Castle on Facebook
Chief Scientific Officer
Owen Wallace
  Owen Wallace LinkedIn Profile  Owen Wallace Twitter Account  Owen Wallace News  Owen Wallace on Facebook
Vice President
Silvia Buonamici
  Silvia Buonamici LinkedIn Profile  Silvia Buonamici Twitter Account  Silvia Buonamici News  Silvia Buonamici on Facebook
Vice President
Alexander Flohr
  Alexander Flohr LinkedIn Profile  Alexander Flohr Twitter Account  Alexander Flohr News  Alexander Flohr on Facebook
Vice President
Giorgio Ottaviani
  Giorgio Ottaviani LinkedIn Profile  Giorgio Ottaviani Twitter Account  Giorgio Ottaviani News  Giorgio Ottaviani on Facebook
VP - Bus. Development
Jullian Jones
  Jullian Jones LinkedIn Profile  Jullian Jones Twitter Account  Jullian Jones News  Jullian Jones on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/25/2020: MineralTree venture capital transaction
Next: 9/25/2020: Petal venture capital transaction

 

Share this article

 


Where The Data Comes From

We report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary